PRDX2, peroxiredoxin 2, 7001

N. diseases: 243; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.370 AlteredExpression disease BEFREE The expression of PRDX2 at both mRNA and protein levels was examined by q‑RT‑PCR, western blotting and immunohistochemical assessment in HCC tissues and cell line HCCLM3. 30747220 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.370 AlteredExpression disease BEFREE In this study, we investigated the link between Prx2 and CSC stemness through regulation of ROS levels in hepatocellular carcinoma (HCC) cells. 30611866 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.370 Biomarker disease BEFREE Moreover, C<sub>12</sub>-PRP displayed no cytotoxicity against human liver carcinoma HepG2 and human embryonic kidney HEK-293 cell lines. 29437631 2018
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.370 GeneticVariation disease BEFREE Prx II is FoxM1-dependently-expressed antioxidant in HCC and function as an enhancer of Ras(G12V) oncogenic potential in hepatic tumorigenesis through activation of ERK/FoxM1/cyclin D1 cascade. 26500057 2016
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.370 Biomarker disease BEFREE We found that Torin-2 effectively suppressed the growth and survival of HCC cell lines, demonstrated by reduced proliferation and a high rate of apoptosis. 26239364 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.370 Biomarker disease BEFREE TSA selectively induced uc002mbe.2 in four studied HCC cell lines. 23643933 2013
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.370 Biomarker disease CTD_human Hepatocellular carcinoma-associated protein markers investigated by MALDI-TOF MS. 21472284 2012
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.370 Biomarker disease BEFREE We analyzed the effects of TSA, a specific and potent HDAC inhibitor, on the human hepatoma cell lines HepG2 and Huh-7. 12494463 2003
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.340 Biomarker disease BEFREE Designing therapeutics targeting Prx2 may offer a novel strategy for developing treatments for prostate cancer, including castration-resistant prostate cancer, which is dependent on AR signaling. 21539911 2011
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.340 Biomarker disease CTD_human Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression. 17566973 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.340 Biomarker disease BEFREE Ectopic expression of a partial sequence of PTX1 (Met84 - Leu225) as a VP22-fusion protein in prostate cancer cell line, PC-3, induced cellular senescence. 16989575 2006
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.340 AlteredExpression disease BEFREE Effects of PTX1 expression on growth and tumorigenicity of the prostate cancer cell line PC-3. 12932305 2003
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.340 AlteredExpression disease BEFREE Molecular cloning, expression, localization, and gene organization of PTX1, a human nuclear protein that is downregulated in prostate cancer. 11445006 2001
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.330 Biomarker group BEFREE The expression levels of ZNF667-AS1 and ZNF667 were significantly reversed by treatment with 5-Aza-dC and TSA in esophageal cancer cell lines. 31804468 2019
CUI: C0546837
Disease: Malignant neoplasm of esophagus
Malignant neoplasm of esophagus
0.330 Biomarker disease BEFREE The expression levels of ZNF667-AS1 and ZNF667 were significantly reversed by treatment with 5-Aza-dC and TSA in esophageal cancer cell lines. 31804468 2019
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.330 AlteredExpression group BEFREE The expression level of CTC-276P9.1 in esophageal cancer cells was significantly reversed by treatment with 5-Aza-dC and TSA. 29524086 2018
CUI: C0546837
Disease: Malignant neoplasm of esophagus
Malignant neoplasm of esophagus
0.330 AlteredExpression disease BEFREE The expression level of CTC-276P9.1 in esophageal cancer cells was significantly reversed by treatment with 5-Aza-dC and TSA. 29524086 2018
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.330 Biomarker group BEFREE We reported 4 differentially expressed proteins involved in the pathological process of esophageal cancer, such as annexinA1 (ANXA1), peroxiredoxin-2 (PRDX2), transgelin (TAGLN) andactin-aortic smooth muscle (ACTA2). 28392898 2017
CUI: C0546837
Disease: Malignant neoplasm of esophagus
Malignant neoplasm of esophagus
0.330 Biomarker disease BEFREE We reported 4 differentially expressed proteins involved in the pathological process of esophageal cancer, such as annexinA1 (ANXA1), peroxiredoxin-2 (PRDX2), transgelin (TAGLN) andactin-aortic smooth muscle (ACTA2). 28392898 2017
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.330 Biomarker group CTD_human Comparative proteomic analysis of esophageal squamous cell carcinoma. 15986332 2005
CUI: C0546837
Disease: Malignant neoplasm of esophagus
Malignant neoplasm of esophagus
0.330 Biomarker disease CTD_human Comparative proteomic analysis of esophageal squamous cell carcinoma. 15986332 2005
CUI: C0013080
Disease: Down Syndrome
Down Syndrome
0.330 AlteredExpression disease BEFREE Moreover, while up-regulation of Prx II appears to provide evidence for the existence of compensatory response in increased cell loss, up-regulation of Prx VI may be used to discriminate PD from AD as well as DS. 12650976 2003
CUI: C0013080
Disease: Down Syndrome
Down Syndrome
0.330 AlteredExpression disease LHGDN This suggests that the decreased expression of PRDX2 may contribute to the altered redox state in DS at levels comparable to that of the increased expression of SOD1. 12943237 2003
CUI: C0013080
Disease: Down Syndrome
Down Syndrome
0.330 AlteredExpression disease BEFREE This suggests that the decreased expression of PRDX2 may contribute to the altered redox state in DS at levels comparable to that of the increased expression of SOD1. 12943237 2003
CUI: C0013080
Disease: Down Syndrome
Down Syndrome
0.330 AlteredExpression disease LHGDN Moreover, while up-regulation of Prx II appears to provide evidence for the existence of compensatory response in increased cell loss, up-regulation of Prx VI may be used to discriminate PD from AD as well as DS. 12650976 2003